



PATENT

ATTORNEY DOCKET NO. 50164/011002

Certificate of Mailing: Date of Deposit: June 19, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Rosemarie Perullo

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jost-Price et al.	Confirmation No.:	4333
Serial No.:	10/500,544	Art Unit:	1614
Filed:	March 15, 2005	Examiner:	Not Yet Assigned
Customer No.:	21559		
Title:	COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS AND PROLIFERATIVE SKIN DISEASES		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.


Submission of this statement is not a representation that a search has been made,
nor is the inclusion of information in this statement an admission that the information is
material to patentability.

This statement is being filed before the receipt of a first Office action on the
merits.

If there are any charges or any credits, please apply them to Deposit Account No.
03-2095.

Respectfully submitted,

Date: 6/19/06



Michael J. Belliveau, Ph.D.
Reg. No. 52,608

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Sheet 1 of 2

SUBSTITUTE INFORMATION TO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/011002
		Serial No.	10/500,544
		Applicant	Jost-Price et al.
		Filing Date	March 15, 2005
		Group	1614
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		IDS Filed	June 19, 2006
		(37 C.F.R. § 1.98(b))	

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	RE 35,068	Oct. 17, 1995	Tanaka et al.			
	3,729,568	Apr. 24, 1973	Kligman			
	4,009,282	Feb. 22, 1977	Voorhees			
	4,113,882	Sep. 12, 1978	Okazaki et al.			
	4,181,725	Jan. 1, 1980	Voorhees et al.			
	4,201,788	May 6, 1980	Voorhees et al.			
	4,214,000	Jul. 22, 1980	Papa			
	4,254,145	Mar. 3, 1981	Birnbaum			
	4,603,146	Jul. 29, 1986	Kligman			
	4,621,100	Nov. 4, 1986	Lund et al.			
	4,888,342	Dec. 19, 1989	Kligman			
	5,015,481	May 14, 1991	Franz et al.			
	5,093,360	Mar. 3, 1992	Yu et al.			
	5,134,163	Jul. 28, 1992	Kligman			
	5,310,759	May 10, 1994	Bockman			
	5,654,312	Aug. 5, 1997	Andrulis, Jr. et al.			
	6,008,254	Dec. 28, 1999	Kligman et al.			
	6,031,001	Feb. 29, 2000	Stjerschantz et al.			
	6,046,244	Apr. 4, 2000	Büyüktimkin et al.			
	6,228,887	May 8, 2001	Kligman et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/011002
	Serial No.	10/500,544
	Applicant	Jost-Price et al.
	Filing Date	March 15, 2005
	Group	1614
	IDS Filed	June 19, 2006

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Widomski et al., "The Prostaglandin Analogs, Misoprostol and SC-46275, Potently Inhibit Cytokine Release from Activated Human Monocytes," <i>Immunopharmacol. Immunotoxicol.</i> 19:165-174 (1997).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	